Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes

Core Viewpoint - Sharp Therapeutics Corp. is initiating a non-brokered private placement of unsecured convertible notes totaling up to US$3.0 million, with the aim of using the proceeds for general working capital purposes [1]. Group 1: Note Offering Details - The proposed Note Offering will consist of notes with a principal amount of US$1,000 each, convertible into common shares at a price of US$2.00 per share [2]. - Each note will bear an interest rate of 6.0% per annum, calculated as simple interest and payable in cash on the maturity date [3]. - The notes will convert into common shares if the company completes an equity financing of at least US$7,000,000 prior to the maturity date, with a 20-day notice to note holders [4]. Group 2: Participation and Commitments - STX Partners, LLC and other insiders have confirmed their intention to participate in the Note Offering [5]. - The company previously announced a common share offering at US$2.50 per share, expected to close in the first quarter of 2026, with proceeds also aimed at general working capital [6]. - STX, the largest shareholder, has committed to purchase at least 1,600,000 common shares, contingent upon raising at least US$6,000,000 from other investors [7]. Group 3: Regulatory and Offering Conditions - The offerings will be conducted as private placements under Canadian securities laws and may also be offered in the U.S. under applicable exemptions [9]. - All issued notes and common shares will be subject to a four-month hold period and require approval from the TSX Venture Exchange [10]. - The insider participation in the offerings is classified as a related-party transaction, exempt from formal valuation or minority shareholder approval due to the market capitalization criteria [8]. Group 4: Company Overview - Sharp Therapeutics is a preclinical-stage company focused on developing small-molecule therapeutics for genetic diseases, utilizing a discovery platform that combines high throughput screening technologies [11].